A recombinant partial protein sequence (within amino acids 200-300) from the human protein was used as the immunogen for the OLIG2 antibody.
Olig2, a basic helix-loop-helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue.
